Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451ROBERTS, W. Gregory; WHALEN, Pamela M; ATHERTON, James A et al.Cancer research (Baltimore). 2005, Vol 65, Num 3, pp 957-966, issn 0008-5472, 10 p.Article

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cellsBARBACCI, E. Gabriella; PUSTILNIK, Leslie R; KATH, John C et al.Cancer research (Baltimore). 2003, Vol 63, Num 15, pp 4450-4459, issn 0008-5472, 10 p.Article

The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere templateKATH, John C; DIRICO, Amy P; GLADUE, Ronald P et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2163-2167, issn 0960-894X, 5 p.Article

Novel CCR1 antagonists with improved metabolic stabilityBROWN, Matthew F; AVERY, Mike; LIRA, Paul D et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2175-2179, issn 0960-894X, 5 p.Article

Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2) : Structure-activity relationships and strategies for the elimination of reactive metabolite formationWALKER, Daniel P; BI, F. Christopher; MCGLYNN, Molly A et al.Bioorganic & medicinal chemistry letters (Print). 2008, Vol 18, Num 23, pp 6071-6077, issn 0960-894X, 7 p.Article

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitorJANI, Jitesh P; FINN, Richard S; MORRIS, Joel et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9887-9893, issn 0008-5472, 7 p.Article

Potent small molecule CCR1 antagonistsKATH, John C; BRISSETTE, William H; MARTIN, William H et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2169-2173, issn 0960-894X, 5 p.Article